Cytokine Signalling Forum

Publications





October 17

Resultados Informados por los Pacientes (PROs) de Baricitinib en Pacientes con Artritis Reumatoide sin tratamiento o con tratamiento previo limitado con fármacos antirreumáticos modificadores de la enfermedad

Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo W, Won J, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, Zerbini C.
Arthritis Res Ther. 2017 Sep 18;19(1):208

RA-BEGIN was a Phase 3, double-blind randomised active comparator-controlled study to evaluate baricitinib as monotherapy or in combination with MTX in patients with active RA who were naïve to csDMARDS and bDMARDS. In this analysis of the RA-BEGIN study, baricitinib alone or with MTX when used as initial therapy resulted in significant improvements in most patient-reported outcome measures compared with MTX. At baseline, study participants had active RA, impaired physical function, mode...

Keywords: JAK, Baricitinib, Clinical, PRO

Translated by: Igor Kos